MK-3475/BCG in High Risk Superficial Bladder Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a single center Phase I safety and efficacy study of MK-3475 therapy used in
combination with bladder infused BCG treatment for patients, 18 years or older, with high
risk superficial bladder cancer (cancer not yet involving the muscle of the bladder wall) who
have had removal of their bladder tumor. Patients will be enrolled to a single treatment
group of a fixed dose of MK 3475 and BCG.